Literature DB >> 21300465

Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience.

Daniela Thorwarth1, Guido Henke, Arndt-Christian Müller, Matthias Reimold, Thomas Beyer, Andreas Boss, Armin Kolb, Bernd Pichler, Christina Pfannenberg.   

Abstract

PURPOSE: To evaluate intensity-modulated radiotherapy (IMRT) treatment planning based on simultaneous positron-emission tomography and magnetic resonance imaging (PET/MRI) of meningioma. METHODS AND MATERIALS: A meningioma patient was examined prior to radiotherapy with dedicated planning computed tomography (CT), MRI, PET/CT with gallium-68-labeled DOTATOC (68Ga-DOTATOC), and simultaneous 68Ga-DOTATOC-PET/MRI. The first gross target volume (GTV) was defined based on a combination of separate MR and 68Ga-DOTATOC-PET/CT imaging (GTVPET/CT+MR). Then, the simultaneous PET/MR images were used to delineate a second GTV (GTVPET/MR) by following exactly the same delineation strategy. After an isotropic expansion of those volumes by a 4-mm safety margin, the resulting planning target volumes (PTVs) were compared by calculating the intersection volume and the relative complements. A cross-evaluation of IMRT plans was performed, where the treatment plan created for the PTVPET/CT+MR was applied to the PET/MR-based PTVPET/MR.
RESULTS: Generally, target volumes for IMRT treatment planning did not differ between MRI plus 68Ga-DOTATOC-PET/CT and simultaneous PET/MR imaging. Only in certain regions of the GTV were differences observed. The overall volume of the PET/MR-based PTV was approximately the same as that obtained from PET/CT data. A small region of infiltrative tumor growth next to the main tumor mass was better visualized with combined PET/MR due to smaller PET voxel sizes and improved recovery. An IMRT treatment plan was optimized for the PTVPET/CT+MR. The evaluation of this plan with respect to the PTVPET/MR showed parts of the target volume that would not have received the full radiation dose after delineation of the tumor, based on simultaneous PET/MR.
CONCLUSION: This case showed that differences in target volumes delineated on the basis of separate MR and PET/CT and simultaneous PET/MR may be observed that can have significant consequences for an effectively applied radiotherapy treatment plan.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21300465     DOI: 10.1016/j.ijrobp.2010.10.078

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  21 in total

Review 1.  Functional MRI for radiotherapy dose painting.

Authors:  Uulke A van der Heide; Antonetta C Houweling; Greetje Groenendaal; Regina G H Beets-Tan; Philippe Lambin
Journal:  Magn Reson Imaging       Date:  2012-07-06       Impact factor: 2.546

Review 2.  Hybrid MR-PET in Neuroimaging.

Authors:  S Bisdas; C Lá Fougere; U Ernemann
Journal:  Clin Neuroradiol       Date:  2015-07-31       Impact factor: 3.649

Review 3.  Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview.

Authors:  Punit Sharma; Anirban Mukherjee
Journal:  Ann Transl Med       Date:  2016-02

Review 4.  Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer's perspective.

Authors:  Antonis Kalemis; Bénédicte M A Delattre; Susanne Heinzer
Journal:  MAGMA       Date:  2012-08-07       Impact factor: 2.310

Review 5.  Combined PET/MR: Where are we now? Summary report of the second international workshop on PET/MR imaging April 8-12, 2013, Tubingen, Germany.

Authors:  Dale L Bailey; Henryk Barthel; Bettina Beuthin-Baumann; Thomas Beyer; Sotirios Bisdas; Ronald Boellaard; Johannes Czernin; Alexander Drzezga; Ulrike Ernemann; Christiane Franzius; Brigitte Gückel; Rupert Handgretinger; Markus Hartenbach; Dirk Hellwig; Helen Nadel; Stephan G Nekolla; Thomas Pfluger; Bernd J Pichler; Harald H Quick; Osama Sabri; Bernhard Sattler; Jürgen Schäfer; Fritz Schick; Barry A Siegel; Heinz P Schlemmer; Nina F Schwenzer; Jörg van den Hoff; Patrick Veit-Haibach; Hans F Wehrl
Journal:  Mol Imaging Biol       Date:  2014-06       Impact factor: 3.488

6.  [Molecular imaging in neurological diseases].

Authors:  M Reimold; C la Fougère
Journal:  Radiologe       Date:  2016-07       Impact factor: 0.635

Review 7.  Competitive advantage of PET/MRI.

Authors:  Hossein Jadvar; Patrick M Colletti
Journal:  Eur J Radiol       Date:  2013-06-18       Impact factor: 3.528

8.  68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?

Authors:  Michael Sommerauer; Jan-Karl Burkhardt; Karl Frontzek; Elisabeth Rushing; Alfred Buck; Niklaus Krayenbuehl; Michael Weller; Niklaus Schaefer; Felix P Kuhn
Journal:  Neuro Oncol       Date:  2016-02-09       Impact factor: 12.300

9.  Comparison of ⁶⁸Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results.

Authors:  Ali Afshar-Oromieh; Maya B Wolf; Clemens Kratochwil; Frederik L Giesel; Stephanie E Combs; Antonia Dimitrakopoulou-Strauss; Regula Gnirs; Matthias C Roethke; Heinz P Schlemmer; Uwe Haberkorn
Journal:  Neuro Oncol       Date:  2014-07-09       Impact factor: 12.300

Review 10.  Simultaneous PET-MRI in oncology: a solution looking for a problem?

Authors:  Thomas E Yankeelov; Todd E Peterson; Richard G Abramson; David Izquierdo-Garcia; David Garcia-Izquierdo; Lori R Arlinghaus; Xia Li; Nkiruka C Atuegwu; Ciprian Catana; H Charles Manning; Zahi A Fayad; John C Gore
Journal:  Magn Reson Imaging       Date:  2012-07-15       Impact factor: 2.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.